Scientific Program Day One
Wednesday | June 26, 2024
과학 프로그램 1 일 차
科学议程第一天
カンファレンス １日目
7:00 am Coffee & Check-In
7:50 am Chair’s Opening Remarks
Outlining Clinical Updates & Clinical Progression in Field to Ensure a Smooth Translation Into the Clinic
8:00 am Exploring the Clinical Development of ADCs in China to Understand Progress in the Region
Synopsis
- Review a brief history and progress of ADCs to date
- Discuss clinical development of ADCs around the world and in China
- Look into the future: opportunities and challenges
8:30 am Exploring the Clinical Results of MRG003 & MRG004A to Develop EFGR Targeted ADCs
Synopsis
- Comprehensive review of five ADCs currently in clinical studies
- Outline updated clinical results on nasopharyngeal carcinoma and HNSCC for MRG003, an EGFR targeted ADC
- Gain a clinical update for MRG004A, a TF targeted ADC
9:00 am From Product to Platform: Henlius’ Practices & Progress in ADC to Address Unmet Medical Needs
Synopsis
- Review how ADC is a strategic R&D field of Henlius based on its 13+ year antibody capabilities and integrated R&D platform
- Explore the highlights of ADC assets' progress in clinical and pre-clinical stages
- Learn how Henlius is dedicated in building ADC platform – “Hanjugator”
9:30 am Leveraging ThioBridge™ Linker Technology for Successful IND Submission
Synopsis
- Learn strategies to achieve uniform and stable attachment, ensuring high stability, potency, and efficacy of bioconjugates
- Understand the versatility and innovative features of Abzena’s ThioBridge™ linker technology
- Hear case studies demonstrating the developability of ThioBridge™-based molecules on the path to IND submission
10:00 am Business Card Exchange Hour
Synopsis
This session is an opportunity to connect with peers, exchange business cards, and hold in-depth conversations with some of the brightest minds in the ADC field to establish meaningful and lasting relationships.
Honing Novel Innovations in ADC Technologies Coming Out of Asia to Establish Competitive Differentiation
11:00 am Exploring ADCs With Site-Specific Conjugation, DAR of 8 or 12, & Payloads With Dual Drugs to Turbocharge ADC Innovation
Synopsis
- Discuss the “CHO-TEM” technology, combining CHO Pharma’s “glycan modification” technology, and T-E Meds’ “drug bundles” technology
- Outline how antibody molecule glycans are modified with one enzyme to create 4 azido groups, to which 4 drug bundles each with 2 or 3 drugs of two categories are linked
- Learn how to produce homogeneous ADCs with high DAR (8 or 12), and dual drugs
11:30 am Analyzing the Benefits of First-in-Class Stroma Targeting ADC
Synopsis
- Learn how high stroma is a key mechanism leading to resistance in hard-to-treat tumors
- Assess an innovative target that was identified on tumor stroma
- Discuss how a stroma-targeting ADC demonstrates strong in vivo efficacy and deepens responses of cancer cell targeting ADC
12:00 pm Our History to Serve Innovators: A Step Ahead Against the Challenges of the Bioconjugates
Synopsis
- Discover the insides of a sustainable business model
- Learn about expertise, technology and integration of services
- Discuss capacity shortage challenges: what it means going forward
12:30 pm
Networking Lunch
1:30 pm Exploring the Advantages of Using Bispecific ADCs & Their Impact on Efficacy & Toxicity to Increase Patient Treatability
Synopsis
- Discuss proof of concept study of a bispecific ADC
- Review the recent development progress of a bispecific ADC
- Assess the benefit of bispecific ADC in terms of efficacy and toxicity
2:00 pm Reviewing the Development of DXd ADC Technology & the Latest Clinical Results
Synopsis
- Gain an overview of the DXd-ADC technology platform
- Receive updates on clinical development of T-DXd
- Discuss updates on preclinical and clinical development of early DXd assets, such as R-DXd, DS-3939, etc.
2:30 pm Exploring the OBI Pharma ADC Assets & the GlycOBI™ Platform
Synopsis
- Discover how OBI Pharma has developed a unique glycan ADC platform (GlycOBI™) to enable a site-specific conjugation, which is in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in various DAR
- Review how assets using the GlycOBI™ platform have the potential for improved in vivo efficacy, better safety profile, and enhanced stability in animal studies
- Share data about how Anti-Nectin-4, -TROP2, HER2, and bi-specific ADCs were developed based on OBI’s GlycOBI™ platform
3:00 pm ADC: Process, Manufacturing, & Quality (CMC)
Synopsis
- Providing an overview of the development history, mechanism of action, and future direction of ADC products
- Highlighting the key considerations in the processdevelopment and scale-up production of ADC products, including bare antibodies, drug substance (DS), and drug product (DP)
- Exploring the comprehensive quality management strategy and essential research methods for assessing the key quality attributes of ADC products
3:30 pm Afternoon Networking Break
4:00 pm Development of Eribulin-based Antibody-Drug Conjugates
Synopsis
- Introduction of Eribulin-based ADC BB-1701 and BB-1705
- Discussion of preclinical results of Eribulin-based ADCs
- Progress of BB-1701 phase 1/2 clinical development
4:30 pm Extractables Studies on Single-Use Components in ADC Manufacturing
Synopsis
- Evaluating DMSO and DMA on wetted components
- Discussing extractables study test design
- Understanding safety assessment of extractables
Exploring Global Manufacturing Capabilities & the Challenges With Antibody & LinkerPayload Supply Chain to Reduce Process Complexity & Standardize ADC Development
5:00 pm Panel Discussion: Mastering Supply Chain Issues in Sourcing Antibodies, Linkers & Payloads to Asia to Plan Ahead & Reduce Lead Times
Synopsis
- Understanding why supply chain is a bigger problem in the APAC region
- Dealing with a different time zone: the pros and cons
- Navigating the difficulty of accessing the European and American markets
5:30 pm Empowering Revolutionary Conjugation Technology Into CMC Development & GMP Manufacturing of ADC Therapeutics
Synopsis
- Discuss integrated conjugation manufacturing platform
- Review a continuous conjugation manufacturing process
- Outline a quality control strategy
6:00 pm Chair’s Closing Remarks
6:05 pm Drinks Reception & Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings